The neurologist from Cleveland Clinic discussed the importance of studying real-world outcomes in patients with migraine using CGRPs such as eptinezumab.
Zubair Ahmed, MD
Advertisement
Articles by Zubair Ahmed, MD
The duo from Cleveland Clinic discussed their presentation from AHS 2021 regarding the effects of COVID-19 on access to telemedicine visits among minorities.
The neurologist from Cleveland Clinic provided perspective on why there is a need for continued pressure to research and understand more about COVID-19 and its association with headache.
Advertisement
Latest Updated Articles
Improving Use of Telemedicine in Minority Communities: Aarushi Suneja, MD; Zubair Ahmed, MDPublished: July 4th 2021 | Updated:
Characterizing Real-World Outcomes With Eptinezumab in Migraine: Zubair Ahmed, MDPublished: July 17th 2021 | Updated:
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves Doxecitine and Doxribtimine Combination Therapy as First Treatment for Thymidine Kinase 2 Deficiency
2
Exploring Long-Term Efficacy of Inebilizumab in Phase 3 Myasthenia Gravis Trial: Richard Nowak, MD, MS
3
Alexander Gold, MD, on Adrabetadex’s Impact in Infantile-Onset Niemann-Pick C
4
Showcasing Sustained Benefits in Myasthenia Gravis Research at AANEM 2025: Kimberly Moran, PhD, MBA
5
